(P020) 3D Conformal External Beam Radiation Therapy May Result in Lower Heart Dose and Risk of Radiation-Induced Major Coronary Events Compared With Multicatheter Balloon High-Dose-Rate Brachytherapy for Left-Sided Breast Cancer Patients

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Both 3DCRT and balloon HDR can achieve relatively low MHDs and result in minimal increases in the risk of additional major coronary events. In certain cases, compared with HDR brachytherapy, 3DCRT may result in lower MHDs and a lower risk of long-term cardiac toxicity.

Jason C. Ye, MD, Brittney Wilson, BS, CMD, Igor Shuryak, MD, Jenghwa Chang, PhD, Samuel Trichter, MSc, David Brenner, MD, DSc, Dattatreyudu Nori, MD, John Ng, MD; Department of Radiation Oncology, Weill Cornell Medical College; Center for Radiologic Research, Columbia University Medical Center

PURPOSE: To determine and compare the heart dose and potential increased risks in long-term cardiac toxicity from three-dimensional conformal external beam radiation therapy (3DCRT) and multicatheter balloon high-dose-rate (HDR) brachytherapy treatments for left-sided breast cancer patients.

METHODS: Fifteen consecutive patients who were treated with balloon HDR (3,400 cGy in 10 fractions, twice daily) after lumpectomy for left-sided breast cancer between 2011 and 2014 were included in this study. Target volumes drawn for HDR brachytherapy. Left breast, heart, and left anterior descending artery (LAD) were contoured by a physician in the brachytherapy treatment planning system and independently confirmed by another physician. 3DCRT plans (5,040 cGy in 28 fractions using opposed tangential beams) were developed using the same computed tomography (CT) scans and contours by the same team by transferring the image and structure sets to the external beam planning system. Appropriate target coverage, dose distribution, and dose homogeneity (± 7%) were confirmed independently. Cardiac blocks were allowed, as long as they did not significantly affect the breast and lumpectomy cavity coverage. The radiation doses to the heart and LAD using 3DCRT and HDR techniques were recorded. The risk of long-term additional cardiac toxicity was estimated by calculating the 10-year radiation-induced estimated actual risk (EAR) for major coronary events using a previously published cardiac risk model.

RESULTS: The 15 women (median age: 65 yr, range: 59–86 yr) all had early-stage localized disease that fit the American Society for Radiation Oncology (ASTRO) guidelines for accelerated partial breast irradiation. Average of the mean heat doses (MHDs) delivered using HDR was 251.6 cGy (range: 137–427 cGy), while the average MHD that they would have received using 3DCRT was 128.99 cGy (range: 90–236.4 cGy) (Student’s t-test: P < .001). The mean dose to the LAD was not statistically significant (551 cGy for HDR vs 814 cGy for 3DCRT; P = .11 by Student’s t-test). After factoring in MHD, age, smoking status, history of hyperlipidemia, hypertension, and diabetic history, the mean 10-year radiation-induced EAR for 3DCRT and HDR for the 15 women was 0.51% (range: 0.17%–1.51%) and 1.01% (range: 0.31%–3.5%), respectively (Student’s t-test: P = .0064).

CONCLUSIONS: Both 3DCRT and balloon HDR can achieve relatively low MHDs and result in minimal increases in the risk of additional major coronary events. In certain cases, compared with HDR brachytherapy, 3DCRT may result in lower MHDs and a lower risk of long-term cardiac toxicity.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Related Content